blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3202392

EP3202392 - ORAL DOSAGE FORMS COMPRISING LICARBAZEPINE ACETATE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  01.07.2022
Database last updated on 02.07.2024
FormerThe patent has been granted
Status updated on  23.07.2021
FormerGrant of patent is intended
Status updated on  15.03.2021
FormerExamination is in progress
Status updated on  19.04.2019
FormerRequest for examination was made
Status updated on  09.02.2018
FormerThe application has been published
Status updated on  07.07.2017
Most recent event   Tooltip14.06.2024Lapse of the patent in a contracting state
New state(s): TR		published on 17.07.2024 [2024/29]
Applicant(s)For all designated states
BIAL - Portela & Ca., S.A.
À Av. da Siderurgia Nacional
4745-457 S. Mamede do Coronado / PT
[2017/32]
Inventor(s)01 / VASCONCELOS, Téofilo Cardoso de
À Av. da Siderurgia Nacional
4745-457 S. Mamede do Coronado / PT
02 / SANTOS LIMA, Ricardo Jorge dos
À Av. da Siderurgia Nacional
4745-457 S. Mamede do Coronado / PT
03 / CAMPOS COSTA, Rui Cerdeira
À Av. da Siderurgia Nacional
4745-457 S. Mamede do Coronado / PT
 [2017/32]
Representative(s)King, Lawrence
Simmons & Simmons LLP
CityPoint
1 Ropemaker Street
London EC2Y 9SS / GB
[2021/34]
Former [2017/32]King, Lawrence
A.A. Thornton & Co.
10 Old Bailey
London EC4M 7NG / GB
Application number, filing date16180687.224.10.2008
[2017/32]
Priority number, dateUS20070982790P26.10.2007         Original published format: US 982790 P
[2017/32]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3202392
Date:09.08.2017
Language:EN
[2017/32]
Type: B1 Patent specification 
No.:EP3202392
Date:25.08.2021
Language:EN
[2021/34]
Search report(s)(Supplementary) European search report - dispatched on:EP14.06.2017
ClassificationIPC:A61K9/00, A61K9/20, A61K9/16, A61K31/55
[2017/32]
CPC:
A61K31/55 (EP,BR,KR,US); A61K9/2054 (EP,BR,KR,US); A61K47/50 (KR);
A61K9/0053 (EP,BR,US); A61K9/0056 (EP,BR,KR,US); A61K9/14 (KR);
A61K9/16 (BR,US); A61K9/1635 (EP,BR,US); A61K9/1652 (EP,BR,US);
A61K9/1682 (BR,KR,US); A61K9/1694 (EP,BR,US); A61K9/20 (BR,US);
A61K9/2027 (EP,BR,KR,US); A61K9/2077 (KR); A61K9/2095 (EP,BR,KR,US);
A61K9/48 (BR,US); A61K9/4866 (BR,US); A61P25/00 (EP);
A61P25/04 (EP); A61P25/08 (EP); A61P25/18 (EP);
A61P43/00 (EP) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2018/11]
Former [2017/32]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
Extension statesAL26.09.2016
BA26.09.2016
MK26.09.2016
RS26.09.2016
TitleGerman:ORALE DOSIERFORMEN MIT LICARBAZEPIN-ACETAT[2017/32]
English:ORAL DOSAGE FORMS COMPRISING LICARBAZEPINE ACETATE[2017/32]
French:FORMES GALÉNIQUES ORALES RENFERMANT DE L'ACÉTATE DE LICARBAZÉPINE[2017/32]
Examination procedure22.07.2016Date on which the examining division has become responsible
24.11.2016Loss of particular rights, legal effect: Claims
13.01.2017Despatch of communication of loss of particular rights: Claims {1}
01.02.2018Examination requested  [2018/11]
29.05.2018Amendment by applicant (claims and/or description)
25.04.2019Despatch of a communication from the examining division (Time limit: M06)
06.12.2019Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
11.02.2020Reply to a communication from the examining division
25.03.2020Despatch of a communication from the examining division (Time limit: M04)
03.08.2020Reply to a communication from the examining division
15.02.2021Cancellation of oral proceeding that was planned for 18.02.2021
18.02.2021Date of oral proceedings (cancelled)
16.03.2021Communication of intention to grant the patent
16.07.2021Fee for grant paid
16.07.2021Fee for publishing/printing paid
16.07.2021Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP08842368.6  / EP2214636
Opposition(s)27.05.2022No opposition filed within time limit [2022/31]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
11.02.2020Request for further processing filed
11.02.2020Full payment received (date of receipt of payment)
Request granted
21.02.2020Decision despatched
The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
29.05.2018Request for further processing filed
29.05.2018Full payment received (date of receipt of payment)
Request granted
11.06.2018Decision despatched
Loss of rights: Claims
10.03.2017Request for further processing filed
10.03.2017Full payment received (date of receipt of payment)
Request granted
13.04.2017Decision despatched
Fees paidRenewal fee
22.07.2016Renewal fee patent year 03
22.07.2016Renewal fee patent year 04
22.07.2016Renewal fee patent year 05
22.07.2016Renewal fee patent year 06
22.07.2016Renewal fee patent year 07
22.07.2016Renewal fee patent year 08
31.08.2016Renewal fee patent year 09
17.10.2017Renewal fee patent year 10
11.10.2018Renewal fee patent year 11
10.10.2019Renewal fee patent year 12
09.10.2020Renewal fee patent year 13
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU24.10.2008
AT25.08.2021
CY25.08.2021
CZ25.08.2021
DK25.08.2021
EE25.08.2021
FI25.08.2021
HR25.08.2021
LT25.08.2021
LV25.08.2021
MC25.08.2021
NL25.08.2021
PL25.08.2021
RO25.08.2021
SE25.08.2021
SI25.08.2021
SK25.08.2021
TR25.08.2021
IE24.10.2021
LU24.10.2021
BE31.10.2021
BG25.11.2021
NO25.11.2021
GR26.11.2021
IS25.12.2021
[2024/29]
Former [2023/29]HU24.10.2008
AT25.08.2021
CY25.08.2021
CZ25.08.2021
DK25.08.2021
EE25.08.2021
FI25.08.2021
HR25.08.2021
LT25.08.2021
LV25.08.2021
MC25.08.2021
NL25.08.2021
PL25.08.2021
RO25.08.2021
SE25.08.2021
SI25.08.2021
SK25.08.2021
IE24.10.2021
LU24.10.2021
BE31.10.2021
BG25.11.2021
NO25.11.2021
GR26.11.2021
IS25.12.2021
Former [2023/24]AT25.08.2021
CY25.08.2021
CZ25.08.2021
DK25.08.2021
EE25.08.2021
FI25.08.2021
HR25.08.2021
LT25.08.2021
LV25.08.2021
MC25.08.2021
NL25.08.2021
PL25.08.2021
RO25.08.2021
SE25.08.2021
SI25.08.2021
SK25.08.2021
IE24.10.2021
LU24.10.2021
BE31.10.2021
BG25.11.2021
NO25.11.2021
GR26.11.2021
IS25.12.2021
Former [2022/48]AT25.08.2021
CZ25.08.2021
DK25.08.2021
EE25.08.2021
FI25.08.2021
HR25.08.2021
LT25.08.2021
LV25.08.2021
MC25.08.2021
NL25.08.2021
PL25.08.2021
RO25.08.2021
SE25.08.2021
SI25.08.2021
SK25.08.2021
IE24.10.2021
LU24.10.2021
BE31.10.2021
BG25.11.2021
NO25.11.2021
GR26.11.2021
IS25.12.2021
Former [2022/36]AT25.08.2021
CZ25.08.2021
DK25.08.2021
EE25.08.2021
FI25.08.2021
HR25.08.2021
LT25.08.2021
LV25.08.2021
MC25.08.2021
NL25.08.2021
PL25.08.2021
RO25.08.2021
SE25.08.2021
SI25.08.2021
SK25.08.2021
LU24.10.2021
BE31.10.2021
BG25.11.2021
NO25.11.2021
GR26.11.2021
IS25.12.2021
Former [2022/35]AT25.08.2021
CZ25.08.2021
DK25.08.2021
EE25.08.2021
FI25.08.2021
HR25.08.2021
LT25.08.2021
LV25.08.2021
MC25.08.2021
NL25.08.2021
PL25.08.2021
RO25.08.2021
SE25.08.2021
SK25.08.2021
LU24.10.2021
BE31.10.2021
BG25.11.2021
NO25.11.2021
GR26.11.2021
IS25.12.2021
Former [2022/33]AT25.08.2021
CZ25.08.2021
DK25.08.2021
EE25.08.2021
FI25.08.2021
HR25.08.2021
LT25.08.2021
LV25.08.2021
MC25.08.2021
NL25.08.2021
PL25.08.2021
RO25.08.2021
SE25.08.2021
SK25.08.2021
BE31.10.2021
BG25.11.2021
NO25.11.2021
GR26.11.2021
IS25.12.2021
Former [2022/24]AT25.08.2021
CZ25.08.2021
DK25.08.2021
EE25.08.2021
FI25.08.2021
HR25.08.2021
LT25.08.2021
LV25.08.2021
NL25.08.2021
PL25.08.2021
RO25.08.2021
SE25.08.2021
SK25.08.2021
BG25.11.2021
NO25.11.2021
GR26.11.2021
IS25.12.2021
Former [2022/21]AT25.08.2021
DK25.08.2021
FI25.08.2021
HR25.08.2021
LT25.08.2021
LV25.08.2021
NL25.08.2021
PL25.08.2021
SE25.08.2021
BG25.11.2021
NO25.11.2021
GR26.11.2021
IS25.12.2021
Former [2022/16]AT25.08.2021
FI25.08.2021
HR25.08.2021
LT25.08.2021
LV25.08.2021
NL25.08.2021
PL25.08.2021
SE25.08.2021
BG25.11.2021
NO25.11.2021
GR26.11.2021
IS25.12.2021
Former [2022/12]AT25.08.2021
FI25.08.2021
HR25.08.2021
LT25.08.2021
LV25.08.2021
PL25.08.2021
SE25.08.2021
BG25.11.2021
NO25.11.2021
GR26.11.2021
IS25.12.2021
Former [2022/08]AT25.08.2021
FI25.08.2021
LT25.08.2021
SE25.08.2021
BG25.11.2021
NO25.11.2021
Former [2022/07]AT25.08.2021
LT25.08.2021
NO25.11.2021
Documents cited:Search[Y]WO2005092290  (NOVARTIS AG [CH], et al) [Y] 1-73 * examples 1,2 *;
 [XY]US2006252745  (ALMEIDA JOSE L D [PT], et al) [X] 1-42,44-48,73 * paragraph [0031] - paragraph [0032] * [Y] 43,49-72;
 [Y]  - B HANCOCK, "The Relative Densities of Pharmaceutical Powders, Blends, Dry Granulations, and Immediate-Release Tablets", PHARMACEUTICAL TECHNOLOGY, (20030401), pages 64 - 80, XP055064508 [Y] 1-73 * the whole document *
by applicant   - European Pharmacopeia, (2007), pages 285 - 286
    - THE UNITED STATES PHARMACOPEIA CONVENTION, (2008), vol. 1, pages 231 - 232
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.